




RealRate

PHARMACEUTICAL 2020

Anixa Biosciences Inc
Rank 342 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 633% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,098%, being 795% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	6,093
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,481
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,004
Other Liabilities	0
Other Net Income	71
Property and Equipment	201
Research and Development	5,473
Revenues	250
Selling, General and Administrative Expense	5,663

Output Variable	Value in 1000 USD
Assets	6,294
Liabilities	1,481
Expenses	12,140
Stockholders Equity	4,812
Net Income	-11,819
Comprehensive Net Income	-11,819
Economic Capital Ratio	-1,098%